Siddhartha Dutta

TL;DR: In this paper, the authors conducted a systematic review of COVID-19 vaccine trials and found that most of the reactions reported were mild to moderate whereas a few with severe intensity.

TL;DR: Encouraging to see increases in utilization of vitamins/immune boosters and PPE across the countries, however, increases in the utilization and prices of antimicrobials is a concern that needs addressing alongside misinformation and any unintended consequences from the pandemic.

TL;DR: In this paper, the authors focused on cardiovascular adverse events post-COVID-19 vaccination and aims to determine adverse events with the administered vaccine, and extracted the cardiovascular (CVS) adverse events were extracted for three broad headings (SOCs) - cardiac disorders, vascular disorders, and investigations.

TL;DR: This study included 725 patients from an Isolation center, of which 230 were excluded due to reasons like incorrect phone numbers, no response on phone, or denying consent to participate, and there were no reported acute or severe adverse effects with these products.

TL;DR: Favipiravir appears to be a relatively safe drug that may explain the improvement in critically ill patients and reduce inflammatory markers, according to a review of adverse drug events reported in the WHO pharmacovigilance database.